Rare Neurological Disease Treatment is anticipated to have CAGR of ~8.6% over 2019-2028. Neurological diseases which are having less diagnostics and treatment options and is affecting small number of population is known as rare neurological diseases. The diseases target the nervous system, especially the brain, spinal cord, and all the nerves that run in the human body. The market is driven by the increase in prevalence of rare diseases, which would help the industry boost in the forecast period. Furthermore, the evolving trend of orphan drugs and rise in the healthcare expenditure would help the industry gain maximum revenue shares in the coming years. Furthermore, the rapid developments in healthcare sector and the key socioeconomic changes aiding to modify lifestyles is also providing opportunities to key players to expand their footprint within the rare neurological disease treatment industry in the coming years.

Top Driver: Surge in Prevalence of Rare Neurological Diseases to boost the industry

Rare Neurological Disease Treatment is projected to grow with the surge in the prevalence of the rare neurological diseases in the forecast period. The major rare neurological diseases include narcolepsy, Alzheimer’s disease, Duchenne muscular dystrophy, multiple sclerosis, amyotrophic lateral sclerosis, spinal muscular atrophy (SMA), and others. Furthermore, according to the recent data published by National Institutes of Neurological Disorders and Stroke in 2019, about 7,000 rare neurological diseases have been registered in the US. According to the same study, these conditions are responsible for noteworthy number of morbidity and mortality. Neurological sleep related disorders are anticipated to increase in coming years due to the surge in ageing population globally.

Oral to Make Crucial Contribution to Growth of Global Rare Neurological Disease Treatment Market

Among route of administration segments of the global Rare Neurological Disease Treatment market, oral segment is anticipated to gain highest revenue shares in the forecast period. This owes to the ease in administration and higher shelf-life of the dosage which would help the industry grow in the coming years. Oral route is anticipated to gain highest CAGR, owing to the compatibility of the patient shown propelling the market to grow further. Additionally, the injectables are also contributing to the significant market shares, due to the higher bioavailability of the drugs shown and would propel the industry further in the coming years.

Increase in the awareness to Benefit North American Market

North America is anticipated to gain highest revenue growth than any other country and is anticipated to boost further in the coming years. This is attributed to the growth in healthcare infrastructure and also increasing continuous emphasis on R&D in drugs and treatment of the rare neurological diseases in the region. Furthermore, the growth in the awareness to maintain better quality of life would propel the industry. In Europe, the disease treatment industry is highly bound to various government policies and other market strategies, aiding the industry to gain significant shares in the coming years.

Due to outbreak of COVID-19 the Rare Neurological Disease Treatment is experiencing a downfall due to the lockout of the major hospitals in order to focus upon the COVID-19 patients. However, the increase in the awareness programs through digital platforms is anticipated to help the industry boost in the current scenario.

Players to Focus on Rare Neurological Disease Treatment

The global Rare Neurological Disease Treatment market leaders include Novartis AG, Kedrion Biopharma Inc., US WorldMeds LLC (Solstice Neurosciences LLC), CSL Ltd, Merz Pharma GmbH & Co. KGaA, Aquestive Therapeutics Inc., Bayer AG, Pfizer Inc., Merck & Co. Inc. (EMD Serono Inc.), and Jazz Pharmaceuticals PLC.

Novartis: In April 2018, AveXis, Inc. announced that it had entered into an agreement and plan of merger with Novartis pursuant to which Novartis will acquire AveXis for $218 per share or a total of $8.7 billion in cash. This offer represents a premium of 88 percent to AveXis’ closing price, and a 72 percent premium to the company’s 30-day volume-weighted average stock price. The transaction was unanimously approved by the Boards of Directors of both companies.

Bayer AG: In August 2019, Bayer AG and BlueRock Therapeutics announced an agreement under which Bayer will fully acquire BlueRock Therapeutics, a privately held US-headquartered biotechnology company focused on developing engineered cell therapies in the fields of neurology, cardiology and immunology, using a proprietary induced pluripotent stem cell (iPSC) platform.

Merck: In December 2019, Merck, known as MSD outside the United States and Canada, and ArQule, Inc. announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire ArQule for $20 per share in cash for an approximate total equity value of $2.7 billion. ArQule is a publicly traded biopharmaceutical company focused on kinase inhibitor discovery and development for the treatment of patients with cancer and other diseases. ArQule’s lead investigational candidate, ARQ 531, is a novel, oral Bruton’s tyrosine kinase (BTK) inhibitor currently in a Phase 2 dose expansion study for the treatment of B-cell malignancies.

Scope of the Report

By Drug Type

• Biologics
• Small Molecules

 By Route of Administration

• Injectable
• Oral
• Others

By Region

• North America
• Europe
• Asia Pacific
• LAMEA

Key Reasons to Purchase this Report

1. It provides a technological development map over time to understand the growth rate of the industry.
2. The report offers a dynamic method to various factors that drive or restrain the growth of the market.
3. It renders definite analysis for changing competitive dynamics.
4. It builds a seven-year estimate based on how the market is predicted to grow.